(ARGX) argenx - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 49.554m USD | Total Return: 37.2% in 12m
Avg Turnover: 269M
Qual. Beats: -1
Rev. Trend: 94.1%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
Confidence
argenx NV (ARGX) is a commercial-stage biopharmaceutical company focused on developing antibody-based therapies for autoimmune diseases. Its primary product, efgartigimod (marketed as VYVGART), utilizes neonatal Fc receptor (FcRn) blockade to reduce pathogenic IgG antibodies. This mechanism is currently applied to several high-unmet-need conditions, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
The company operates within the biotechnology sector, where business models often rely on a pipeline-in-a-product strategy to expand a single molecules indications across multiple therapeutic areas. argenx leverages strategic partnerships with global firms such as AbbVie, Zai Lab, and Halozyme to scale its development and distribution capabilities across the United States, Europe, and Asia.
The firms pipeline includes several early-stage candidates targeting IL-6, Galectin-10, and immunoglobulin A to address various inflammatory disorders. Reviewing the fundamental valuation metrics on ValueRay can help determine if the companys current stock price aligns with its long-term growth prospects. Based in Amsterdam, the company maintains a diverse portfolio of engineered antibodies aimed at chronic orphan diseases.
- VYVGART sales growth in generalized Myasthenia Gravis drives near-term revenue performance
- CIDP indication launch and market penetration accelerate long-term commercial scaling
- Pipeline expansion into multisystem autoimmune diseases reduces single-indication clinical risk
- High research and development expenses pressure operating margins despite rising product sales
- Strategic partnerships with Zai Lab and AbbVie provide critical international market access
| Net Income: 1.32b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 12.16 > 1.0 |
| NWC/Revenue: 119.4% < 20% (prev 116.6%; Δ 2.80% < -1%) |
| CFO/TA 0.10 > 3% & CFO 850.5m > Net Income 1.32b |
| Net Debt (-4.31b) to EBITDA (1.37b): -3.15 < 3 |
| Current Ratio: 5.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (66.2m) vs 12m ago 0.66% < -2% |
| Gross Margin: 90.11% > 18% (prev 0.90%; Δ 8.92k% > 0.5%) |
| Asset Turnover: 62.76% > 50% (prev 58.24%; Δ 4.52% > 0%) |
| Interest Coverage Ratio: 325.8 > 6 (EBITDA TTM 1.37b / Interest Expense TTM 4.12m) |
| A: 0.64 (Total Current Assets 6.90b - Total Current Liabilities 1.32b) / Total Assets 8.68b |
| B: -0.03 (Retained Earnings -279.8m / Total Assets 8.68b) |
| C: 0.18 (EBIT TTM 1.34b / Avg Total Assets 7.44b) |
| D: -0.15 (Book Value of Equity -198.8m / Total Liabilities 1.36b) |
| Altman-Z'' = 5.17 = AAA |
| DSRI: 1.41 (Receivables 1.66b/909.1m, Revenue 4.67b/3.61b) |
| GMI: 1.00 (GM 90.11% / 89.84%) |
| AQI: 0.97 (AQ_t 0.20 / AQ_t-1 0.21) |
| SGI: 1.29 (Revenue 4.67b / 3.61b) |
| TATA: 0.05 (NI 1.32b - CFO 850.5m) / TA 8.68b) |
| Beneish M = -2.44 (Cap -4..+1) = BBB |
As of May 24, 2026, the stock is trading at USD 806.46 with a total of 170,886 shares traded.
Over the past week, the price has changed by +0.89%,
over one month by +2.35%,
over three months by -2.40% and
over the past year by +37.24%.
argenx has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy ARGX.
- StrongBuy: 14
- Buy: 7
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 1022.9 | 26.8% |
P/E Forward = 29.0698
P/S = 10.4489
P/B = 6.5986
P/EG = 1.2938
Revenue TTM = 4.67b USD
EBIT TTM = 1.34b USD
EBITDA TTM = 1.37b USD
Long Term Debt = 72.7m USD (estimated: total debt 83.5m - short term 10.8m)
Short Term Debt = 10.8m USD (from shortTermDebt, last quarter)
Debt = 130.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 47.2m
Net Debt = -4.31b USD (calculated: Debt 130.6m - CCE 4.44b)
Enterprise Value = 45.2b USD (49.6b + Debt 130.6m - CCE 4.44b)
Interest Coverage Ratio = 325.8 (Ebit TTM 1.34b / Interest Expense TTM 4.12m)
EV/FCF = 53.59x (Enterprise Value 45.2b / FCF TTM 844.3m)
FCF Yield = 1.87% (FCF TTM 844.3m / Enterprise Value 45.2b)
FCF Margin = 18.08% (FCF TTM 844.3m / Revenue TTM 4.67b)
Net Margin = 28.29% (Net Income TTM 1.32b / Revenue TTM 4.67b)
Gross Margin = 90.11% ((Revenue TTM 4.67b - Cost of Revenue TTM 462.2m) / Revenue TTM)
Gross Margin QoQ = 90.68% (prev 90.68%)
Tobins Q-Ratio = 5.21 (Enterprise Value 45.2b / Total Assets 8.68b)
Interest Expense / Debt = 3.15% (Interest Expense 4.12m / Debt 130.6m)
Taxrate = 14.08% (60.0m / 426.0m)
NOPAT = 1.15b (EBIT 1.34b * (1 - 14.08%))
Current Ratio = 5.23 (Total Current Assets 6.90b / Total Current Liabilities 1.32b)
Debt / Equity = 0.02 (Debt 130.6m / totalStockholderEquity, last quarter 7.32b)
Debt / EBITDA = -3.15 (Net Debt -4.31b / EBITDA 1.37b)
Debt / FCF = -5.10 (Net Debt -4.31b / FCF TTM 844.3m)
Total Stockholder Equity = 5.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.76% (Net Income 1.32b / Total Assets 8.68b)
RoE = 21.76% (Net Income TTM 1.32b / Total Stockholder Equity 6.07b)
RoCE = 21.83% (EBIT 1.34b / Capital Employed (Equity 6.07b + L.T.Debt 72.7m))
RoIC = 15.64% (NOPAT 1.15b / Invested Capital 7.37b)
WACC = 7.08% (E(49.6b)/V(49.7b) * Re(7.09%) + D(130.6m)/V(49.7b) * Rd(3.15%) * (1-Tc(0.14)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 5.95%
[DCF] Terminal Value 75.44% ; FCFF base≈844.3m ; Y1≈847.8m ; Y5≈898.1m
[DCF] Fair Price = 293.9 (EV 14.0b - Net Debt -4.31b = Equity 18.3b / Shares 62.2m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.59 | # QB: -1
Revenue Correlation: 94.06 | Revenue CAGR: 98.05% | SUE: 0.85 | # QB: 4
EPS current Quarter (2026-06-30): EPS=5.23 | Chg30d=+7.76% | Revisions=+20% | Analysts=15
EPS next Quarter (2026-09-30): EPS=5.79 | Chg30d=+4.35% | Revisions=-7% | Analysts=14
EPS current Year (2026-12-31): EPS=22.08 | Chg30d=+3.06% | Revisions=+26% | GrowthEPS=+33.2% | GrowthRev=+41.4%
EPS next Year (2027-12-31): EPS=31.42 | Chg30d=+11.41% | Revisions=+33% | GrowthEPS=+42.3% | GrowthRev=+21.7%
[Analyst] Revisions Ratio: +33%